Table 4. ORS impact on the study outcomes during the follow-up.

	IRR or ORa	95% CI
Biting rate
Month 0 to Month 3	0.28	0.21–0.37
Month 4 to Month 6	0.21	0.12–0.38
Proportion of parous females
Month 0 to Month 3	0.65	0.48–0.87
Month 4 to Month 6	1.15	0.67–1.98
Vivax malaria incidence
Month 0 to Month 6	0.46	0.13–1.43
Month 7 to Month 12	0.09	0.01–0.63
Proportion of lambda-cyhalothrin resistant phenotypes
Month 0 to Month 3	2.70	2.00–3.65
Month 4 to Month 6	3.58	2.11–6.03

CI, confidence interval; IRR, incidence rate ration, OR, odds ratio.

^a Coefficient estimate for the interaction term between the ORS group and the follow-up period, considering the control as the reference.